Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria. / Schmidtchen, Artur; Puthia, Manoj.

In: Bio-protocol, Vol. 12, No. 2, e4302, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Schmidtchen, A & Puthia, M 2022, 'Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria', Bio-protocol, vol. 12, no. 2, e4302. https://doi.org/10.21769/BioProtoc.4302

APA

Schmidtchen, A., & Puthia, M. (2022). Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria. Bio-protocol, 12(2), [e4302]. https://doi.org/10.21769/BioProtoc.4302

Vancouver

Schmidtchen A, Puthia M. Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria. Bio-protocol. 2022;12(2). e4302. https://doi.org/10.21769/BioProtoc.4302

Author

Schmidtchen, Artur ; Puthia, Manoj. / Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria. In: Bio-protocol. 2022 ; Vol. 12, No. 2.

Bibtex

@article{ccf3551d88104966a7a717be89984f05,
title = "Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria",
abstract = "Basic and translational research needs rapid methods to test antimicrobial formulations. Bioluminescent bacteria and advanced imaging systems capable of acquiring bioluminescence enable us to quickly and longitudinally evaluate the efficacy of antimicrobials. Conventional approaches, such as radial diffusion and viable count assays, are time-consuming and do not allow for longitudinal analysis. Bioluminescence imaging is sensitive and gives vital spatial and temporal information on the infection status in the body. Here, using bioluminescent Pseudomonas aeruginosa, we describe an in vitro and an in vivo approach to rapidly evaluate the antimicrobial efficacy of the host-defense peptide TCP-25.",
keywords = "Antimicrobials, Bioluminescent, In vivo imaging, In vivo models, Infection",
author = "Artur Schmidtchen and Manoj Puthia",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 The Authors; exclusive licensee Bio-protocol LLC.",
year = "2022",
doi = "10.21769/BioProtoc.4302",
language = "English",
volume = "12",
journal = "Bio-protocol",
issn = "2331-8325",
publisher = "bio-protocol",
number = "2",

}

RIS

TY - JOUR

T1 - Rapid in vitro and in vivo Evaluation of Antimicrobial Formulations Using Bioluminescent Pathogenic Bacteria

AU - Schmidtchen, Artur

AU - Puthia, Manoj

N1 - Publisher Copyright: Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

PY - 2022

Y1 - 2022

N2 - Basic and translational research needs rapid methods to test antimicrobial formulations. Bioluminescent bacteria and advanced imaging systems capable of acquiring bioluminescence enable us to quickly and longitudinally evaluate the efficacy of antimicrobials. Conventional approaches, such as radial diffusion and viable count assays, are time-consuming and do not allow for longitudinal analysis. Bioluminescence imaging is sensitive and gives vital spatial and temporal information on the infection status in the body. Here, using bioluminescent Pseudomonas aeruginosa, we describe an in vitro and an in vivo approach to rapidly evaluate the antimicrobial efficacy of the host-defense peptide TCP-25.

AB - Basic and translational research needs rapid methods to test antimicrobial formulations. Bioluminescent bacteria and advanced imaging systems capable of acquiring bioluminescence enable us to quickly and longitudinally evaluate the efficacy of antimicrobials. Conventional approaches, such as radial diffusion and viable count assays, are time-consuming and do not allow for longitudinal analysis. Bioluminescence imaging is sensitive and gives vital spatial and temporal information on the infection status in the body. Here, using bioluminescent Pseudomonas aeruginosa, we describe an in vitro and an in vivo approach to rapidly evaluate the antimicrobial efficacy of the host-defense peptide TCP-25.

KW - Antimicrobials

KW - Bioluminescent

KW - In vivo imaging

KW - In vivo models

KW - Infection

U2 - 10.21769/BioProtoc.4302

DO - 10.21769/BioProtoc.4302

M3 - Journal article

C2 - 35127992

AN - SCOPUS:85123407176

VL - 12

JO - Bio-protocol

JF - Bio-protocol

SN - 2331-8325

IS - 2

M1 - e4302

ER -

ID: 291536218